Thrombo-embolic Events in Germ-Cell Tumour Patients
Author Information
Author(s): Piketty A-C, Fléchon A, Laplanche A, Nouyrigat E, Droz J-P, Théodore C, Fizazi K
Primary Institution: Institut Gustave Roussy, Villejuif, France
Hypothesis
The study aims to evaluate the risk of thrombo-embolic events in patients with germ-cell tumours receiving cisplatin-based chemotherapy compared to a control group.
Conclusion
Patients with germ-cell tumours are at a higher risk for thrombo-embolic events than those with non-germ-cell cancers while on cisplatin-based chemotherapy.
Supporting Evidence
- 19% of patients with germ-cell tumours experienced thrombo-embolic events compared to 6% in the control group.
- High body surface area and elevated serum lactate dehydrogenase were identified as independent predictors of thrombo-embolic events.
- Patients with no risk factors had a 4% probability of thrombo-embolic events, while those with at least one risk factor had a 26% probability.
Takeaway
This study found that patients with a certain type of cancer are more likely to have blood clots when they get chemotherapy, and doctors can predict who is at risk by looking at their body size and a blood test.
Methodology
The study assessed thrombo-embolic events in 100 patients with germ-cell tumours and compared them to 100 matched controls receiving similar chemotherapy.
Limitations
The study had a relatively small sample size and a high number of parameters tested in univariate analysis.
Participant Demographics
The study included male patients aged over 16 years with pathologic evidence of germ-cell tumours.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI: 13–28
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website